We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

ERS Genomics Licenses CRISPR Gene Editing Technology to Daiichi Sankyo


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "ERS Genomics Licenses CRISPR Gene Editing Technology to Daiichi Sankyo "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ERS Genomics, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, has announced the signing of a license agreement with Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan. The agreement provides Daiichi Sankyo with access to CRISPR/Cas9 genome editing technology intellectual property for use in its internal research and development.

ERS Genomics holds an exclusive worldwide license to the foundational intellectual property covering CRISPR/Cas9 for all applications other than use as a human therapeutic. Under the terms of the license, Daiichi Sankyo is able to use CRISPR technology to support its R&D initiatives to address areas of unmet medical need.

Eric Rhodes, CEO of ERS Genomics, said: “Daiichi Sankyo is our first large pharma licensee in Japan. CRISPR/Cas9 is revolutionary in genome editing; we look forward to observing how the company applies the technology to further advance its R&D operations.”

Financial details of the agreement are not disclosed.

Advertisement